VAERS accepts reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine manufacturers, and the public can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. In large part, reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.
The strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA’s multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as “safety signals.” If a safety signal is found in VAERS, further studies can be done in safety systems such as the CDC’s Vaccine Safety Datalink (VSD) or the Clinical Immunization Safety Assessment (CISA) project. These systems do not have the same scientific limitations as VAERS, and can better assess health risks and possible connections between adverse events and a vaccine.
Key considerations and limitations of VAERS data:
VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.
COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 36-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 23Apr2021 as dose 1, single (Lot number: EW0170), in left arm, on 15May2021 as dose 2, single (Lot number: EW0183), in left arm and on 29Dec2021 as dose 3 (booster), single (Lot number: FJ1611) at the age of 36 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Graves Disease" (unspecified if ongoing), notes: Graves Disease with active hyperthyroidism; "hyperthyroidism" (unspecified if ongoing), notes: Graves Disease with active hyperthyroidism. Concomitant medication(s) included: METHIMAZOLE, start date: 06Oct2021; CITALOPRAM, start date: 01Dec2021; GUANFACINE, start date: 01Dec2021. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 29May2022, outcome "not recovered" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (29May2022) Positive, notes: symptoms were nearly gone but covid test was positive (very pale pink); (31May2022) Positive, notes: symptoms came back fully and tested positive (solid pink). Therapeutic measures were taken as a result of vaccination failure, covid-19. Addition information: Treatment start date was 24May2022. Treatment stop date was 29May2022. Known allergies was no.
|COVID19 (COVID19 (PFIZER-BIONTECH))||3||COVID19||PFIZER\BIONTECH||FJ1611||Unknown||LA|
|LAB_DATA:||Test Date: 20220529; Test Name: COVID-19 Test; Test Result: Positive ; Comments: symptoms were nearly gone but covid test was positive (very pale pink).; Test Date: 20220531; Test Name: COVID-19 Test; Test Result: Positive ; Comments: symptoms came back fully and tested positive (solid pink).|
|OTHER_MEDS:||METHIMAZOLE; CITALOPRAM; GUANFACINE|
|HISTORY:||Medical History/Concurrent Conditions: Graves' disease (Graves Disease with active hyperthyroidism); Hyperthyroidism (Graves Disease with active hyperthyroidism)|